WT1 and neoplasm: Noting the significant presence and immunogenicity of the Wilms’ tumor protein across a range of malignancies [200], mRNA encoding the Wilms’ tumor protein was developed into an autologous dendritic cell vaccine (WT1-mRNA/DC) and has been studied in a single-arm, Phase 1/2 trial of patients with advanced solid cancers who were receiving standard therapy, including 13 patients with GBM [201].